Immuno-oncology spotlight on diverse therapeutic classes

Immune checkpoint inhibitors, such as the multi-billion-dollar drugs Keytruda and Opdivo, have dominated the immuno-oncology landscape in recent years (see Figure 1), but are not the only classes on the market or in development. T-cell engager therapeutics, oncolytic virus therapy and adoptive T-cell therapies were among the promising technologies covered at the fourth annual Immuno-Oncology […]

In multiple myeloma, B-cell maturation antigen emerges as promising target

This is a Cortellis Market Insight report, an ongoing series featuring expert reviews of hot topics in the biopharma field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis were gathered from Cortellis from Clarivate Analytics. There remains an unmet need for patients with multiple myeloma (MM), particularly […]

How Common is In-Office Dispensing of Oral Prostate Cancer Drugs?

The growing trend of physicians dispensing of oral oncolytics directly to patients disrupts the U.S. reimbursement system’s traditional reliance upon insurers’ specialty pharmacies. Key finding:  Three quarters of oncologists and urologists surveyed by DRG reported that their practices have the capability to dispense oral prostate cancer drugs through their practice’s licensed pharmacy (most common) or […]

FDA draft guidance addresses inclusion of adolescents in oncology trials

With an eye toward helping industry, investigators and institutional review boards (IRBs), the U.S. Food and Drug Administration (FDA) has unveiled draft guidance on the inclusion of adolescents—defined as those between the ages of 12 and 17—in adult oncology trials. Allowing adolescents in relevant trials would allow for earlier access to life-saving drugs in this […]

ASCO 2018: paradigm changers and emerging blockbusters

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis was gathered both onsite at ASCO and from Clarivate Analytics Cortellis. The American Society for Clinical Oncology […]

Under ISP, How Will your Plan Assess an Oncology Drug’s Value for an Indication?

    if(“undefined”==typeof window.datawrapper)window.datawrapper={};window.datawrapper[“ITXPo”]={},window.datawrapper[“ITXPo”].embedDeltas={“100″:785,”200″:562,”300″:488,”400″:473,”500″:428,”700″:413,”800″:413,”900″:413,”1000”:398},window.datawrapper[“ITXPo”].iframe=document.getElementById(“datawrapper-chart-ITXPo”),window.datawrapper[“ITXPo”].iframe.style.height=window.datawrapper[“ITXPo”].embedDeltas[Math.min(1e3,Math.max(100*Math.floor(window.datawrapper[“ITXPo”].iframe.offsetWidth/100),100))]+”px”,window.addEventListener(“message”,function(a){if(“undefined”!=typeof a.data[“datawrapper-height”])for(var b in a.data[“datawrapper-height”])if(“ITXPo”==b)window.datawrapper[“ITXPo”].iframe.style.height=a.data[“datawrapper-height”][b]+”px”}); Key finding: For their indication-specific pricing (ISP) programs, 52% of surveyed MCOs identified phase II/III trial data and post-approval research such as phase IV trials as the most important resources for determining an oncology therapy’s value for a new indication. Clinical guidelines also feature prominently with 34% […]

ESMO session explores CDK inhibition and cell cycle modulation in cancer

The principles of CDKs/cyclins in cell-cycle progression Deregulation of the cell cycle is a common feature of human cancer. The mammalian cell cycle is controlled by a subfamily of cyclin-dependent kinases (CDKs), the activity of which is modulated by several activators (cyclins) and inhibitors (INK4, and WAF1/KIP inhibitors). The activity of cell cycle CDKs is […]

Oncology, driven by the promise of IO, dominates biopharma deals landscape

Spurred by the promise of immuno-oncology (IO), oncology dominated the biopharma dealmaking landscape last year, a new article by Jamie Munro and Helen Dowden, of Clarivate Analytics, shows. The acute interest in IO continues a trend, the article noted: The technology has been a factor in 32 of the 35 multibillion-dollar oncology licensing deals over […]

PolyPEPI-1018: A hopeful advance in the fight against cancer – and a milestone for us

Meet PolyPEPI-1018, a cancer vaccine being developed by Treos Bio Ltd. for the treatment of metastatic colorectal cancer. PolyPEPI-1018 contains six synthetic polypeptides that are precisely selected to induce immune cell responses against 12 epitopes from seven cancer testis antigens (CTAs) most frequently expressed in colorectal cancers. These polypeptides are optimized with the PEPI biomarker […]

As biopharma innovation accelerates, partnering follows suit

Last year was a mixed bag for biopharma dealmaking, and not just by the numbers. Lofty valuations tamped down M&A, with buy-side companies also awaiting the outcome of U.S. tax reform. Oncology assets continued to rule, although first-in-class approvals actually showed a decline. And with orphan indications continuing to dominate drug development efforts, the biopharma […]